Thomas Simmerer takes over sales at Carl Zeiss Meditec
Succeeds Ulrich Krauss as member of the management board with responsibility for sales
‘I am looking forward to my new responsibilities and will maintain and expand the successful sales and service structure at Carl Zeiss Meditec in the respective markets,’ said Simmerer.
Simmerer has extensive experience in medical technology. He was in charge of the Microsurgery strategic business unit in Oberkochen from October 2008. Before joining the medical wing of Carl Zeiss, the mechanical engineer led the top-performing business unit, among others, of Dräger Medical in Lübeck from 1996 to 2008. Prior to this, he was responsible for different sales areas at Heraeus in Hanau.
You may also like
Pharma 5.0
ZEISS and Concept Life Sciences partner to advance automated workflows and AI-powered image analysis in spatial biology
The collaboration focusses on high-throughput imaging, AI-driven data analysis and streamlined integration into lab systems, aiming to improve efficiency and data quality for areas such as drug discovery and cancer research
Research & Development
Medicines Discovery Catapult and ZEISS set sights on advancing microscopy in drug discovery
Medicines Discovery Catapult (MDC) and ZEISS have joined forces to improve drug discovery and early development of complex medicines by harnessing the power of advanced microscopy solutions
Analysis
Where Ultra ends, X begins: Shimadzu introduces XPLC
The pressure on analytical laboratories has never been higher. Ultra-high performance liquid chromatography (UHPLC) methods running at 3–5 minutes cannot keep pace with screening volumes in drug discovery, environmental monitoring and contract testing laboratories
Manufacturing
Piramal Pharma Solutions advances sustainability efforts with solar power plant addition at Morpeth, UK Site
Piramal Pharma Solutions is installing a ground-mounted solar power plant (4.3 MWp) at its integrated drug substance and drug product site in Morpeth, UK. The new plant will provide renewable energy directly to the site through a behind-the-meter setup, supporting Piramal’s commitment to reduce Scope 1 and Scope 2 greenhouse gas emissions by 42% by FY2030